TP53 and non-small cell lung carcinoma: Other clinical studies have identified TP53 co-alterations as a negative prognostic marker in EGFR mutated NSCLC and a consistent predictor of worse clinical outcomes with EGFR TKI therapy [3,4,5,7,9,10,12,15].